A path to asthma control for different
patient types
Explore how DUPIXENT may help control symptoms in different
types of patients.
Up to 84% of Adult Asthma Patients Present With Type 2 Inflammation1,2
Your appropriate patients with type 2 inflammation, which can be both systemic and local, may benefit from DUPIXENT today3-5
Allergic Asthma Patient
Clinical Presentation
- 2 severe exacerbations in the past year
- Diagnosed with asthma and chronic allergic rhinitis as a child
- Positive perennial-aeroallergen skin test
-
Compromised lung function:
70%
FEV1 % predicted - EOS: 155 cells/µL
- IgE: 180 IU/mL
Treatment Goals
- Wishes to engage in more physical activity without triggering an exacerbation and seeking nearby care
- Hopeful to enjoy more activities with friends and family with less wheezing
Severe Asthma Patient
With Elevated Eosinophils
Clinical Presentation
- 2 severe exacerbations requiring SCS bursts
- Diagnosed with adult-onset asthma at age 23
- Negative test to allergens
- Mucus hypersecretion with poor asthma control
-
Compromised lung function:
55%
FEV1 % predicted - EOS as high as 650 cells/µL
Treatment Goals
- Hoping to reduce trips to the emergency department as a result of multiple exacerbations
- Ready to enjoy more activities with less shortness of breath
OCS-Dependent Asthma
Patienta
a
Biomarker testing not required
for this patient type.
Clinical Presentation
- Experiences chest tightness and constant wheezing. Frequent exacerbations have led to multiple hospitalizations
- Diagnosed with adult-onset asthma at age 23
-
Has been prescribed courses
of oral corticosteroids for her
severe asthma over the past year,
leading to the following6:
- Feelings of anxiety and depression
- Weight gain
- Adult onset of diabetes
- Hypertension
Treatment Goals
- Hoping to reduce or eliminate OCS
- Looking to control her asthma long term so she can spend more quality time with her family
Child With
Moderate-to-Severe
Uncontrolled Asthma
Clinical Presentation
- 2 exacerbations in the past year, requiring hospitalizations
- Diagnosed with allergic rhinitis
- Suffers from poor lung function, potentially leading to impaired lung development
- Currently receiving a burst of systemic corticosteroids, which are associated with lower height in adulthood, infection, and behavioral changes7
- EOS: 610 cells/µL
- IgE: 558 IU/mL
Treatment History
- Despite high-dose inhaled steroids, he has missed multiple school days over the past year
- Unable to try out for sports teams due to asthma symptoms
- Family avoids engaging in physical activities while on vacation
Patient profiles are representative and are not actual DUPIXENT patients.
Examples of patients with moderate-to-severe eosinophilic phenotype or with OCS-dependent asthma.
FEV1, forced expiratory volume in 1 second; SCS, systemic corticosteroid.